Medicamen Biotech Ltd vs Nectar Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 253.3 as of 30 Apr 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of Nectar Lifescience Ltd changed from 21.5 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of Nectar Lifescience Ltd changed from ₹ 417.13 crore on March 2021 to ₹ 515.35 crore on March 2025 . This represents a CAGR of 4.32% over 5 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of Nectar Lifescience Ltd for the Dec '25 is ₹ 88.81 crore as compare to the Sep '25 revenue of ₹ 0.74 crore. This represent the growth of 11901% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of Nectar Lifescience Ltd for the Dec '25 is ₹ 33.53 crore as compare to the Sep '25 ebitda of ₹ -175 crore. This represent the decline of -119% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of Nectar Lifescience Ltd changed from ₹ 2.97 crore to ₹ 14.27 crore over 7 quarters. This represents a CAGR of 145.20% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of Nectar Lifescience Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Nectar Lifescience Ltd

Nectar Lifescience Limited was initially incorporated on June 27, 1995 as 'Surya Medicare Limited'.
On March 26, 2004, Company changed the name from 'Surya Medicare Limited' to 'Nectar Lifescience Limited'.
NECLIFE is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products.
It is a global pharmaceutical company specializing in Cephalosporins.
Nectar excels in Cephalosporin APIs production with certified facilities meeting global standards.

FAQs for the comparison of Medicamen Biotech Ltd and Nectar Lifescience Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Nectar Lifescience Ltd?

Market cap of Medicamen Biotech Ltd is 343 Cr while Market cap of Nectar Lifescience Ltd is 240 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Nectar Lifescience Ltd?

The stock performance of Medicamen Biotech Ltd and Nectar Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Nectar Lifescience Ltd?

As of May 3, 2026, the Medicamen Biotech Ltd stock price is INR ₹253.3. On the other hand, Nectar Lifescience Ltd stock price is INR ₹12.4.

How do dividend payouts of Medicamen Biotech Ltd and Nectar Lifescience Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Nectar Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.